

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 February 2025 (06.02.2025)



(10) International Publication Number
WO 2025/026353 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) *A61P 19/00* (2006.01)
C12N 15/63 (2006.01) *A61P 35/00* (2006.01)
A61P 21/00 (2006.01)

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/CN2024/108822

(22) International Filing Date:

31 July 2024 (31.07.2024)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/110569

01 August 2023 (01.08.2023) CN

(71) Applicant: **LAEKNA THERAPEUTICS SHANGHAI CO., LTD.** [CN/CN]; 5th Floor, 987 Cailun Road, Zhangjiang, Pudong New Area, Shanghai 201203 (CN).

(72) Inventors: **ZHANG, Ruipeng**; 5th Floor, 987 Cailun Road, Zhangjiang, Pudong New Area, Shanghai 201203 (CN). **YANG, Mengxue**; 5th Floor, 987 Cailun Road, Zhangjiang, Pudong New Area, Shanghai 201203 (CN). **LU, Chris Xiangyang**; 5th Floor, 987 Cailun Road, Zhangjiang, Pudong New Area, Shanghai 201203 (CN). **GU, Xiang-Ju Justin**; 5th Floor, 987 Cailun Road, Zhangjiang, Pudong New Area, Shanghai 201203 (CN). **HU, Meijuan**; 5th Floor, 987 Cailun Road, Zhangjiang, Pudong New Area, Shanghai 201203 (CN).

(74) Agent: **AFD CHINA INTELLECTUAL PROPERTY LAW OFFICE**; Tower B, 21st Fl. Suite 2108, 38 Xueqing Road, Haidian District, Beijing 100083 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: ANTI-ACVR2B ANTIBODIES AND USES THEREOF

(57) Abstract: Provided are anti-ACVR2B antibodies or antigen binding fragment thereof and uses thereof for inhibiting or antagonizing ACVR2B. The antibodies and antigen binding fragments may be used in therapeutic methods for treating ACVR2B or ACVR2B ligands associated diseases or disorders, which are ameliorated or improved by inhibition of ACVR2B.



WO 2025/026353 A1